Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Picton Mahoney Asset Management

Key Points

• Picton Mahoney Asset Management increased its stake in Natera by 24.2% during the first quarter, owning approximately 0.09% of the company, valued at $16.75 million.
• Natera reported quarterly earnings of ($0.50) per share, beating estimates, with a revenue of $501.83 million, up 36.5% year-over-year.
• Analyst ratings for Natera are generally positive, with a consensus rating of "Moderate Buy" and price targets ranging up to $218.00.

Picton Mahoney Asset Management boosted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 24.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 118,467 shares of the medical research company's stock after purchasing an additional 23,077 shares during the period. Picton Mahoney Asset Management owned approximately 0.09% of Natera worth $16,753,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fulton Bank N.A. raised its holdings in Natera by 2.0% during the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after buying an additional 71 shares during the period. QRG Capital Management Inc. boosted its holdings in shares of Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after buying an additional 81 shares during the period. Bridges Investment Management Inc. increased its position in shares of Natera by 5.5% in the first quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company's stock worth $237,000 after acquiring an additional 87 shares in the last quarter. Colonial Trust Co SC raised its holdings in shares of Natera by 7.8% during the fourth quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock valued at $210,000 after acquiring an additional 96 shares during the period. Finally, Silvercrest Asset Management Group LLC lifted its position in shares of Natera by 3.6% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 2,812 shares of the medical research company's stock valued at $445,000 after acquiring an additional 98 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 6,980 shares of the firm's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $150.10, for a total value of $1,047,698.00. Following the transaction, the chief executive officer directly owned 185,182 shares in the company, valued at approximately $27,795,818.20. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the transaction, the director owned 8,118 shares in the company, valued at $1,358,628.48. This trade represents a 34.62% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,844 shares of company stock worth $7,488,466 over the last 90 days. Insiders own 7.60% of the company's stock.

Natera Price Performance

NASDAQ NTRA opened at $138.00 on Tuesday. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The stock's 50-day moving average is $158.49 and its two-hundred day moving average is $156.59. The firm has a market cap of $18.84 billion, a P/E ratio of -93.88 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. During the same period last year, the business earned ($0.56) EPS. The firm's revenue was up 36.5% compared to the same quarter last year. On average, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on NTRA. Barclays lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Evercore ISI initiated coverage on Natera in a research report on Monday. They set an "outperform" rating and a $170.00 price target on the stock. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Finally, UBS Group raised their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and a consensus target price of $183.76.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.